Int J Biol Sci 2011; 7(5):536-550. doi:10.7150/ijbs.7.536
Signal Transducer and Activator of Transcription 3 in Liver Diseases: A Novel Therapeutic Target
1. Laboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD 20892, USA;
2. Laboratory of Liver Pathophysiology, INSERM, U955, Créteil, F-94000 France;
3. Université Paris-Est, Faculté de Médecine, UMR-S955, Créteil, F-94000 France.
Wang H, Lafdil F, Kong X, Gao B. Signal Transducer and Activator of Transcription 3 in Liver Diseases: A Novel Therapeutic Target. Int J Biol Sci 2011; 7(5):536-550. doi:10.7150/ijbs.7.536. Available from http://www.ijbs.com/v07p0536.htm
Signal transducer and activator of transcription 3 (STAT3) is a transcription factor that is activated by many cytokines and growth factors and plays a key role in cell survival, proliferation, and differentiation. STAT3 activation is detected virtually in all rodent models of liver injury and in human liver diseases. In this review, we highlight recent advances of STAT3 signaling in liver injury, steatosis, inflammation, regeneration, fibrosis, and hepatocarcinogenesis. The cytokines and small molecules that activate STAT3 in hepatocytes may have therapeutic benefits to treat acute liver injury, fatty liver disease, and alcoholic hepatitis, while blockage of STAT3 may have a therapeutic potential to prevent and treat liver cancer.
Keywords: STAT3, STAT3 signaling, liver injury, liver diseases